ArticleJournal of the Society for Cardiovascular Angiography & Interventions2026
Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: Patients with obesity undergoing transcatheter aortic valve replacement (TAVR) remain at elevated risk for recurrent heart failure (HF) and cardiorenal events. Tirzepatide produces substantial weight loss and metabolic improvement, but its impact in post-TAVR populations is unknown. Methods: We performed a retrospective study using the TriNetX Global Collaborative Network. Adults with obesity who underwent TAVR between January 1, 2020, and January 1, 2025, were included. Patients initiating tirzepatide after TAVR were compared with patients not receiving tirzepatide. The primary outcome included HF events, while secondary outcomes were acute kidney injury (AKI), acute myocardial infarction (AMI), and ischemic stroke (IS). Fall events were prespecified as a falsification end point. Associations were evaluated using hazard ratios (HRs) with 95% CIs. Results: Propensity score matching (1:1) balanced demographic characteristics, comorbidities, medications, and laboratory characteristics, yielding 421 patients in each cohort. Over 1 year of follow-up, tirzepatide use was associated with a significantly lower hazard of HF (HR, 0.68; 95% CI, 0.56-0.83) and AKI (HR, 0.63; 95% CI, 0.43-0.93). Associations with AMI (HR, 0.81; 95% CI, 0.48-1.37) and IS (HR, 0.726; 95% CI, 0.45-1.17) were not statistically significant. The falsification end point was likewise similar between groups (HR, 0.82; 95% CI, 0.47-1.43). Conclusions: Among patients with obesity undergoing TAVR, tirzepatide use was associated with a lower hazard of HF and AKI within 1 year. No significant association was observed for AMI or IS. These findings suggest potential cardiorenal benefits of tirzepatide in high-risk structural heart populations and warrant prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.